Biocon Pharma Secures NMPA Approval for Tacrolimus Capsules in China

Biocon Pharma Ltd has secured approval from China's National Medical Products Administration (NMPA) for its Tacrolimus capsules available in 0.5mg, 1mg, and 5mg dosages. Tacrolimus, an immunosuppressive medication, is utilized to inhibit organ rejection in transplant recipients by diminishing the immune response of the body. This endorsement boosts Biocon’s range of intricate drug products and further solidifies its position in the worldwide pharmaceutical market.

"This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the company, has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National Medical Products Administration (NMPA), China," Biocon said in a regulatory filing. "The approval further adds to Biocon’s portfolio of complex drug products and will be commercialised in the region expeditiously," Biocon added.

Biocon announced a net profit of ?27.1 crore for the second quarter ending September 30, 2024, reflecting an 84.2% decline year-on-year (YoY). In the same quarter of the previous fiscal year, Biocon reported a net profit of ?172 crore, as stated by the company in a regulatory filing. The firm's operational revenue rose by 3.7% to ?3,590.4 crore compared to ?3,462 crore in the second quarter of FY24.